Omni Bridgeway funds Australian class action against J&J

Omni Bridgeway has agreed to fund an Australian class action brought by JGA Saddler against Johnson & Johnson Pacific Pty Ltd on behalf of individuals who purchased Codral, Sudafed or Benadryl branded oral cold and flu medicines containing Phenylephrine (“PE”) as the active ingredient during the period of 2005 to 2024.

The U.S. Food and Drug Administration recently announced it is proposing to remove oral PE as an active ingredient that can be used in over-the-counter monograph drug products for the temporary relief of nasal congestion after an agency review of the available data determined that oral phenylephrine is not effective for this use.

The claim alleges that J&J breached the consumer guarantees in sections 54 and 56 of the Australian Consumer Law and that J&J’s conduct in marketing PE as an effective nasal decongestant was misleading and deceptive.

Read more.